Ligand id: 8965

Name: fasinumab

No information available.
Summary of Clinical Use
Fasinumab is being evaluated as a monotherapy in Phase III clinical trial (NCT02620020) for its potential to treat chronic low back pain.
Mechanism Of Action and Pharmacodynamic Effects
An extensive body of evidence indicates a pivotal contribution of NGF to pain mechanisms in the adult mammalian nervous system, with elevated levels of NGF reported in several painful conditions in humans [1-2]. Fasinumab specifically neutralizes the biological actions of human NGF, and this is expected to produce clinical pain relief [3].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02620020 A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pain Phase 2/Phase 3 Interventional Regeneron Pharmaceuticals